cDC1, marked by CD141+ in human and CD103+ in mouse, excels in cross-presentation and priming of tumor antigens to CD8+ T cells; cDC2, marked by CD1c+ in human and CD11b+ in mouse, mainly primes CD4+ T cells. This evidence concerns the gene CD8A and neoplasm.